This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Animal Mesenchymal Stem Cell Engineering
Animal mesenchymal stem cells, as an important stem cell type with significant application potential, are widely used in basic cell biology research, animal breeding, and the advancement of animal cell therapies. BioVenic focuses on the core technologies of mesenchymal stem cells in scientific research and provides customized solutions to optimize tissue engineering. Our technical team designs and develops strategies to promote MSC delivery and regulate MSC activity from several important perspectives: direct cell modification, cell exosomes, and three-dimensional culture systems. We conduct standardized research on various parameters for animal MSCs to promote the smooth progress of research.
Fig.1 MSC Engineering in Companion Animal Cell Therapy Development.1,2
Mesenchymal Stem Cell Genetic Engineering
BioVenic provides a comprehensive animal stem cell genome editing technology to provide customized services to the scientific community to engineer mesenchymal stem cells genetically. There is significant heterogeneity among animal MSCs. We genetically engineer mesenchymal stem cells to enhance their regenerative capacity, making them an attractive cell source for animal cell therapy research. By using CRISPR-Cas9 gene editing technology, we introduce specific genetic modifications into mesenchymal stem cells, significantly increasing their viability and passage time in vitro. Our gene editing technology for mammalian cells has been improved and optimized in several aspects, such as precise off-target detection and high efficiency. In the face of challenges such as limitations due to animal age and health, delivery method, and tissue availability for treatment, we have the ability to tailor personalized and functional MSCs for customers using mesenchymal stem cell engineering.
Mesenchymal Stem Cell Secretome Engineering
Extracellular vesicles (ECVs) produced by animal MSCs include exosomes, microvesicles, and apoptotic bodies. ECVs represent the potential to exert the effects of MSCs in a cell-free manner. Its main advantage is avoiding immune-related side effects that can occur when MSCs are administered intravenously. ECV has been shown to enhance M2 macrophages through prostaglandin E2 (PGE2) activation like MSCs. At the same time, MSC-derived ECV is beneficial for respiratory diseases, kidney diseases, and liver diseases. They can also be used to treat bone, joint, and heart-brain-related animal diseases. Angiogenesis and elasticity of damaged tendons in stallions improved after ECV treatment. In dogs, ECVs promote vascularization, collagen synthesis, and skin wound healing better than the cells from which they are derived.
Through years of project accumulation and mastery of cutting-edge technologies in animal cell biology, BioVenic collaborates with scientific researchers to explore and study the MSC secretome. Our secretome engineering mainly focuses on developing standardized procedures for ECV isolation and purification, establishing standard measurement methods for ECV purity, and verifying the mechanism of action of ECV. These areas represent the major limitations of ECV research. We are committed to helping researchers unravel the diverse biological functions of each type of ECV and its unlimited potential in the field of cell therapy research.
Mesenchymal Stem Cell 3D Printing Engineering
BioVenic provides a sophisticated technology for the design and development of three-dimensional animal cell culture, which includes scaffold systems and 3D culture systems. BioVenic's three-dimensional MSC culture solution is designed for researchers in related fields, especially in the field of MSC cell therapy. We aim to facilitate vital processes such as MSC chondrogenesis, differentiation, and proliferation.
Applications of MSCs in Animal Diseases
| Species | Diseases | Applications |
| Canine | Osteoarthritis | Intra-articular injection of adipose-derived stem cells (ASC) is effective in treating osteoarthritis of the elbow joint in dogs, leading to improvements in pain, lameness, range of motion, and functional ability. |
| Osteochondritis | Intra-articular injection of MSCs significantly reduces pain and improves the functional ability of affected individuals. | |
| Tendonitis and Ligaments Rupture | Autologous adipose MSCs for tendon treatment regulate the inflammatory response post-tendon repair by upregulating prostaglandin reductase 1, M2 macrophages, and proteins essential for tendon formation. This process facilitates optimal healing of scar tissue. | |
| Atopic Dermatitis | The immunomodulatory effects of MSC inhibit the activation of T cells and B cells, the release of anti-inflammatory cytokines, and reduce the proliferation of IL-4 and IFN, thereby decreasing the production of IgE. | |
| Feline | Asthma | MSCs had a positive effect on airway remodeling, reduced airway hyperresponsiveness, and decreased airway eosinophilia. |
| Kidney Disease | Intravenous injection of feline amniotic membrane-derived allogeneic MSCs resulted in a significant improvement in proteinuria, a decrease in serum creatinine levels, and a slight enhancement in urine-specific gravity. | |
| Chronic Gingivostomatitis | MSCs perform immunomodulation by normalizing immune cell subsets, serum protein levels, and cytokine levels. | |
| Inflammatory Bowel Disease | MSCs have immunomodulatory and anti-inflammatory effects. After the intravenous injection of MSCs, the clinical symptoms of sick cats improved or completely disappeared. | |
| Bovine | Chronic Wound Healing | MSCs participate in clearing dead cells and necrotic tissue, promoting angiogenesis, reducing scar tissue formation, aiding in wound contraction, and stimulating epithelial regeneration, thereby promoting wound healing, and reducing local inflammation. |
| Mastitis | MSCs exhibit antimicrobial activity, enhance the expression of anti-inflammatory cytokines, antimicrobial peptides, and angiogenic genes in the milk of animals treated for mastitis, and reduce the expression of pro-inflammatory cytokines. | |
| Reproductive System Diseases | MSCs from various sources are utilized in the treatment of metritis, bilateral ovarian dystrophy, ovarian cysts, and reproductive system lesions. | |
| Diabetes Mellitus | MSCs differentiate into islet-like clusters that express insulin and glucagon. |
Why Choose Us?
BioVenic has extensive experience in research and projects related to animal mesenchymal stem cells, ensuring the professionalism and cutting-edge nature of its solutions.
BioVenic has mastered various technical methods closely related to animal mesenchymal stem cell engineering to fulfill the requirements of a wide range of projects effectively.
BioVenic offers timely and professional technical support throughout the entire solution implementation process to address various challenges encountered in animal MSC engineering.
BioVenic not only masters the research methods of animal mesenchymal stem cells from various species and sources at a technical level but also accurately directs the optimization of tissue engineering toward practical applications. Our MSC engineering solutions differ from individual technical services or research platforms. We are dedicated to assisting scientific researchers with designing and implementing comprehensive optimization strategies with clear objectives. From cell genome modification and exosome research to the development of three-dimensional culture systems, our services address the technical challenges currently encountered in the application of MSCs. If you are struggling with how to easily use MSCs in your research, please feel free to contact us to discuss your research plan.
References
- Image retrieved from "Graphical Abstract" Baouche et al., 2023, used under [CC BY 4.0] (https://creativecommons.org/licenses/by/4.0/). The original title was changed to "MSC Engineering in Companion Animal Cell Therapy Development."
- Baouche, Meriem, et al. "Mesenchymal stem cells: generalities and clinical significance in feline and canine medicine." Animals 13.12 (2023): 1903.